You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Daily and Localized NSAID Sonophoresis for Symptomatic Treatment of Knee Osteoarthritis

    SBC: ZETROZ SYSTEMS LLC            Topic: R

    Project Summary: Osteoarthritis (OA) is the most common type of arthritis, affecting over 30 million adults in the United States in 2015 and represents over 25% of medical office visits according to the Centers for Disease Control and Prevention and the National Institutes of Health. Over 40% of individuals over 65 have symptomatic OA and reduced mobility due to the disease. OA pain is often mitig ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Robust System Health Management for Deep Space Missions

    SBC: QUALTECH SYSTEMS, INC.            Topic: X6

    One of NASArsquo;s key challenges in moving its human spaceflight activities from low Earth orbit to the Moon and beyond is the need for increased autonomy and diagnostic capabilities to address system failures. The far greater distance impacts many aspects of these missions and the vehicles and habitational modules necessary to achieve them. A key aspect of on-board autonomy for most if not all N ...

    SBIR Phase II 2020 National Aeronautics and Space Administration
  3. Combat Systems of the Future

    SBC: Rite-solutions, Inc.            Topic: N05149

    During Phase I, the Rite-Solutions team has explored enabling technologies critical to the Navy's reduced manning objectives. They include mission- and intent-focused displays; expert systems; robust, high availability architectures that result in minimal or no operator maintenance during a mission; and constraint based reasoning. In the interest of constraining our initial look to a manageable su ...

    SBIR Phase II 2007 Department of DefenseNavy
  4. Producing Polyclonal Human Antibodies to Anthrax

    SBC: HEMATECH, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Anthrax is a high risk bioterrorist threat. Despite high dose antibiotic therapy, several deaths occurred following the 2001 mail attack. Passive immunization with anti-anthrax immunoglobulins, in combination with

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  5. Clinical Evaluation of NoGo Trap Therapy in Chronic SCI

    SBC: RENETX BIO, INC.            Topic: NINDS

    Summary Approximately 300,000 patients suffer from persistent neurological impairment due to chronic spinal cord injury (SCI) in the United States. Currently, there are no FDA-approved drugs to promote neurologic recovery in patients suffering from the life-long, profound impairments due to chronic SCI. An effective neurorestorative therapy would significantly improve the ability of patients to co ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV

    SBC: Carogen Corporation            Topic: 300

    The ultimate objective of this SBIR project is to develop an immunotherapy based on our recently patented virus-like vesicle (VLV) platform for the treatment of chronic hepatitis B (CHB). The goal of this project is to complete preclinical studies and product development of the CARG-201 vaccine. We have designed this vector to achieve a functional cure in CHB patients, characterized by a sustained ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease

    SBC: BIOPEPTIDES CORP            Topic: NIAID

    Abstract Project Summary There is an obvious need for new approaches and better assays for the laboratory diagnosis of Lyme disease. All attempts to develop a practical assay for the direct detection of Borrelia burgdorferi in infected patients have failed. Thus far, all proposed alternatives to serology have been unsuccessful, not cost-effective, or are still in early development. Improving serol ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  8. An Efficacy Trial of a Digital Therapeutic for Suicide Prevention

    SBC: OUI THERAPEUTICS INC            Topic: 104

    ABSTRACT Suicide is one of the top ten causes of death in the US and suicide rates have increased steadily over the last twenty years. Currently, the most effective treatment options are cognitive behavioral therapies for suicide prevention (CBT-SP), which have been shown to reduce both suicide attempt (SA) risk and suicide ideation (SI). However, access to these treatments is limited because ther ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Synthetic microparticle malaria vaccine

    SBC: ARTIFICIAL CELL TECHNOLOGIES INC            Topic: NIAID

    DESCRIPTION provided by applicant This Phase II project will develop a novel synthetic microparticle vaccine for malaria using the T BT epitopes of the circumsporozoite CS protein of Plasmodium falciparum the causative agent of human malaria There is no approved vaccine for malaria a disease that causes up to million new infections and million deaths each year in the developing wor ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. A serologic assay to measure successful Lyme borreliosis antibiotic therapy

    SBC: L2 DIAGNOSTICS LLC            Topic: R

    DESCRIPTION provided by applicant Lyme disease LD caused by the Ixodes tick borne spirochete Borrelia burgdorferi Bb is the most common vector borne disease in the United States Despite public health preventive measures the annual confirmed case incidence has risen to over the vast majority of which occur in the Northeast Disseminated infection causes disease in the skin heart ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government